
NYSEHealthcareDrug Manufacturers - General
أحدث البيانات المتاحة
1,347.11 US$
−4.01 US$ · -0.30%
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
الإغلاق السابق
1,347.11 US$
−4.01 US$ · -0.30%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
نطاق اليوم
السعر الحالي 1,347.11 US$
نطاق 52 أسبوعًا
السعر الحالي 1,347.11 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
شراء
تقييم
80
أقل من القيمة
المشاعر
71
صعودي
المخاطر
22
مخاطر متوسطة
الزخم
54
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
نطاق اليوم
السعر الحالي 1,347.11 US$
نطاق 52 أسبوعًا
السعر الحالي 1,347.11 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 65.18 مليار USD | 45.04 مليار USD | 34.12 مليار USD | 28.54 مليار USD | 28.32 مليار USD |
| تكلفة البضاعة المباعة | 11.05 مليار USD | 8.42 مليار USD | 7.08 مليار USD | 6.63 مليار USD | 7.31 مليار USD |
| الربح الإجمالي | 54.13 مليار USD | 36.63 مليار USD | 27.04 مليار USD | 21.91 مليار USD | 21.01 مليار USD |
| البحث والتطوير | 13.34 مليار USD | 10.99 مليار USD | 9.31 مليار USD | 7.19 مليار USD | 7.03 مليار USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 11.09 مليار USD | 8.59 مليار USD | 6.94 مليار USD | 6.44 مليار USD | 6.43 مليار USD |
| نفقات التشغيل | 24.43 مليار USD | 19.59 مليار USD | 16.25 مليار USD | 14.78 مليار USD | 14.65 مليار USD |
| دخل الفوائد | 153.3 مليون USD | 175.2 مليون USD | 173.6 مليون USD | 62.8 مليون USD | 25.4 مليون USD |
| مصاريف الفوائد | 795.3 مليون USD | 780.6 مليون USD | 485.9 مليون USD | 331.6 مليون USD | 339.8 مليون USD |
| الاستهلاك والإطفاء | 2 مليار USD | 1.77 مليار USD | 1.53 مليار USD | 1.52 مليار USD | 1.55 مليار USD |
| الدخل التشغيلي | 29.7 مليار USD | 17.04 مليار USD | 10.79 مليار USD | 7.13 مليار USD | 6.36 مليار USD |
| صافي الدخل | 20.64 مليار USD | 10.59 مليار USD | 5.24 مليار USD | 6.24 مليار USD | 5.58 مليار USD |
تم تحديث حقائق الشركة 22 نوفمبر 2026.
النتائج المعلنة مع توقعات الإجماع المتاحة.
النتائج المعلنة مع توقعات الإجماع المتاحة.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
1,447.88 US$
ارتفاع محتمل بنسبة 7.48%صناديق متداولة تفصح عن تعرضها لهذا السهم.
State Street SPDR S&P 500 ETF1557.T2.09 ترليون1.74%119.91 ترليون JPY0.09%113,700 JP¥-3.19%
Vanguard S&P 500 ETFVOO30.14 مليار1.74%1 ترليون USD0.03%635.54 US$-3.41%
Vanguard Morningstar Total Stock Market ETFVTI30.1 مليار1.65%689.3 مليار USD0.03%340.02 US$-3.52%
iShares Core S&P 500 ETFIVV14.56 مليار1.75%803.41 مليار USD0.03%693.71 US$-3.52%
State Street SPDR S&P 500 ETFSPY13.17 مليار1.74%756.38 مليار USD0.09%689.81 US$-3.64%
Vanguard Morningstar Growth ETFVUG12.51 مليار3.37%221 مليار USD0.03%75.69 US$-5.32%
State Street Health Care Select Sector SPDR ETFXLV7.89 مليار16.81%46.92 مليار USD0.08%177.24 US$-0.12%
Vanguard Dividend Appreciation ETFVIG6.43 مليار4.72%115.8 مليار USD0.04%235.69 US$-1.87%
State Street SPDR S&P 500 ETF1557.T
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Total Stock Market ETFVTI
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Growth ETFVUG
State Street Health Care Select Sector SPDR ETFXLV
Vanguard Dividend Appreciation ETFVIGالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.